Jump to content

Asthma

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by PeteThePill (talk | contribs) at 19:49, 13 December 2008 (→‎Medical: correct against to agonist). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For other uses, see Asthma (disambiguation).
Asthma
SpecialtyPulmonology, immunology Edit this on Wikidata

Asthma is a very common chronic disease involving the respiratory system in which the airways occasionally constrict, become inflamed, and are lined with excessive amounts of mucus, often in response to one or more triggers.[1] These episodes may be triggered by such things as exposure to an environmental stimulant such as an allergen, environmental tobacco smoke, cold or warm air, perfume, pet dander, moist air, exercise or exertion, or emotional stress. In children, the most common triggers are viral illnesses such as those that cause the common cold.[2] This airway narrowing causes symptoms such as wheezing, shortness of breath, chest tightness, and coughing. The airway constriction responds to bronchodilators. Between episodes, most patients feel well but can have mild symptoms and they may remain short of breath after exercise for longer periods of time than the unaffected individual. The symptoms of asthma, which can range from mild to life threatening, can usually be controlled with a combination of drugs and environmental changes.

Public attention in the developed world has recently focused on asthma because of its rapidly increasing prevalence, affecting up to one in four urban children.[3]

Signs and symptoms

In some individuals asthma is characterized by chronic respiratory impairment. In others it is an intermittent illness marked by episodic symptoms that may result from a number of triggering events, including upper respiratory infection, stress, airborne allergens, air pollutants (such as smoke or traffic fumes), or exercise. Some or all of the following symptoms may be present in those with asthma: dyspnea, wheezing, stridor, coughing, a tightness and itching of the chest or an inability for physical exertion. Some asthmatics who have severe shortness of breath and tightening of the lungs never wheeze or have stridor and their symptoms may be confused with a COPD-type disease.

An acute exacerbation of asthma is commonly referred to as an asthma attack. The clinical hallmarks of an attack are shortness of breath (dyspnea) and either wheezing or stridor.[4] Although the former is "often regarded as the sine qua non of asthma",[4] some patients present primarily with coughing, and in the late stages of an attack, air motion may be so impaired that no wheezing may be heard. When present the cough may sometimes produce clear sputum. The onset may be sudden, with a sense of constriction in the chest, breathing becomes difficult, and wheezing occurs (primarily upon expiration, but can be in both respiratory phases).

Signs of an asthmatic episode include wheezing, prolonged expiration, a rapid heart rate (tachycardia), rhonchous lung sounds (audible through a stethoscope), the presence of a paradoxical pulse (a pulse that is weaker during inhalation and stronger during exhalation), and over-inflation of the chest. During a serious asthma attack, the accessory muscles of respiration (sternocleidomastoid and scalene muscles of the neck) may be used, shown as in-drawing of tissues between the ribs and above the sternum and clavicles.

During very severe attacks, an asthma sufferer can turn blue from lack of oxygen, and can experience chest pain or even loss of consciousness. Just before loss of consciousness, there is a chance that the patient will feel numbness in the limbs and palms may start to sweat. The person's feet may become icy cold. Severe asthma attacks, which may not be responsive to standard treatments (status asthmaticus), are life-threatening and may lead to respiratory arrest and death. Despite the severity of symptoms during an asthmatic episode, between attacks an asthmatic may show few or even no signs of the disease.[5]

Cause

Asthma is caused by a complex interaction of environmental and genetic factors that researchers do not yet fully understand.[6] These factors can also influence how severe a person’s asthma is and how well they respond to medication.[7] As with other complex diseases, many environmental and genetic factors have been suggested as causes of asthma, but not all of them have been replicated. In addition, as researchers detangle the complex causes of asthma, it is becoming more evident that certain environmental and genetic factors may affect asthma only when combined.

Environmental

Many environmental risk factors have been associated with asthma development and morbidity in children, but a few stand out as well-replicated or that have a meta-analysis of several studies to support their direct association.

Environmental tobacco smoke, especially maternal cigarette smoking, is associated with high risk of asthma prevalence and asthma morbidity, wheeze, and respiratory infections.[8] Poor air quality, from traffic pollution or high ozone levels, has been repeatedly associated with increased asthma morbidity and has a suggested association with asthma development that needs further research.[8][9]

Caesarean sections have been associated with asthma when compared with vaginal birth; a meta-analysis found a 20% increase in asthma prevalence in children delivered by Cesarean section compared to those who were not. It was proposed that this is due to modified bacterial exposure during Cesarean section compared with vaginal birth, which modifies the immune system (as described by the hygiene hypothesis).[10]

Psychological stress, on the part of a child's caregiver, has been associated with asthma and is an area of active research. Stress can modify behaviors that affect asthma, like smoking, but research suggests that stress has other effects as well. There is growing evidence that stress may influence asthma and other diseases by influencing the immune system.[8]

Viral respiratory infections at an early age, along with siblings and day care exposure, may be protective against asthma, although there have been controversial results, and this protection may depend on genetic context.[8][11][12] Antibiotic use early in life has been linked to development of asthma in several examples; it is thought that antibiotics make one susceptible to development of asthma because they modify gut flora, and thus the immune system (as described by the hygiene hypothesis).[13]

The hygiene hypothesis is an hypothesis about the cause of asthma and other allergic disease, and is supported by epidemiologic data for asthma. For example, asthma prevalence has been increasing in developed countries along with increased use of antibiotics, c-sections, and cleaning products.[13][10][14] All of these things may negatively affect exposure to beneficial bacteria and other immune system modulators that are important during development, and thus may cause increased risk for asthma and allergy.

Genetic

Over 100 genes have been associated with asthma in at least one genetic association study.[15] However, such studies must be repeated to ensure the findings are not due to chance. Through the end of 2005, 25 genes had been associated with asthma in six or more separate populations:[15]

Template:Multicol 

 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-break


 Template:Multicol-end

Many of these genes are related to the immune system or to modulating inflammation. However, even among this list of highly replicated genes associated with asthma, the results have not been consistent among all of the populations that have been tested.[15] This indicates that these genes are not associated with asthma under every condition, and that researchers need to do further investigation to figure out the complex interactions that cause asthma. One theory is that asthma is a collection of several diseases, and that genes might have a role in only subsets of asthma. For example, one group of genetic differences (single nucleotide polymorphisms in 17q21) was associated with asthma that develops in childhood.[16]

Gene-environment Interactions

Research suggests that some genetic variants may only cause asthma when they are combined with specific environmental exposures, and otherwise may not be risk factors for asthma.[6]

The genetic trait, CD14 single nucleotide polymorphism (SNP) C-159T and exposure to endotoxin (a bacterial product) are a well-replicated example of a gene-environment interaction that is associated with asthma. Endotoxin exposure varies from person to person and can come from several environmental sources, including environmental tobacco smoke, dogs, and farms. Researchers have found that risk for asthma changes based on a person’s genotype at CD14 C-159T and level of endotoxin exposure.[17]

CD14-endotoxin interaction based on CD14 SNP C-159T[17]
Endotoxin levels CC genotype TT genotype
High exposure Low risk High risk
Low exposure High risk Low risk

Pathophysiology

In asthma, constriction of the airways occurs due to bronchoconstriction and bronchial inflammation. Bronchoconstriction is the narrowing of the airways in the lungs due to the tightening of surrounding smooth muscle. Bronchial inflammation also causes narrowing due to edema and swelling caused by an immune response to allergens.

Bronchoconstriction

Inflamed airways and bronchoconstriction in asthma. Airways narrowed as a result of the inflammatory response cause wheezing.

During an asthma episode, inflamed airways react to environmental triggers such as smoke, dust, or pollen. The airways narrow and produce excess mucus, making it difficult to breathe. In essence, asthma is the result of an immune response in the bronchial airways.[18]

The airways of asthmatics are "hypersensitive" to certain triggers, also known as stimuli (see below). (It is usually classified as type I hypersensitivity.)[19][20] In response to exposure to these triggers, the bronchi (large airways) contract into spasm (an "asthma attack"). Inflammation soon follows, leading to a further narrowing of the airways and excessive mucus production, which leads to coughing and other breathing difficulties.

The normal caliber of the bronchus is maintained by a balanced functioning of these systems, which both operate reflexively. The parasympathetic reflex loop consists of afferent nerve endings which originate under the inner lining of the bronchus. Whenever these afferent nerve endings are stimulated (for example, by dust, cold air or fumes) impulses travel to the brain-stem vagal center, then down the vagal afferent pathway to again reach the bronchus. Acetylcholine is released from the afferent nerve endings. This acetylcholine results in the excessive formation of cyclic Guanine Mono phosphate (cGMP). This initiates bronchoconstriction.

Bronchial inflammation

The mechanisms behind allergic asthma—i.e., asthma resulting from an immune response to inhaled allergens—are the best understood of the causal factors. In both asthmatics and non-asthmatics, inhaled allergens that find their way to the inner airways are ingested by a type of cell known as antigen-presenting cells, or APCs. APCs then "present" pieces of the allergen to other immune system cells. In most people, these other immune cells (TH0 cells) "check" and usually ignore the allergen molecules. In asthmatics, however, these cells transform into a different type of cell (TH2), for reasons that are not well understood. The resultant TH2 cells activate an important arm of the immune system, known as the humoral immune system. The humoral immune system produces antibodies against the inhaled allergen. Later, when an asthmatic inhales the same allergen, these antibodies "recognize" it and activate a humoral response. Inflammation results: chemicals are produced that cause the airways to constrict and release more mucus, and the cell-mediated arm of the immune system is activated. The inflammatory response is responsible for the clinical manifestations of an asthma attack.

Stimuli

Pathogenesis

The fundamental problem in asthma appears to be immunological: young children in the early stages of asthma show signs of excessive inflammation in their airways. Epidemiological findings give clues as to the pathogenesis: the incidence of asthma seems to be increasing worldwide, and asthma is now very much more common in affluent countries.

In 1968 Andor Szentivanyi first described The Beta Adrenergic Theory of Asthma; in which blockage of the Beta-2 receptors of pulmonary smooth muscle cells causes asthma.[25] Szentivanyi's Beta Adrenergic Theory is a citation classic[26] and has been cited more times than any other article in the history of the Journal of Allergy.

In 1995 Szentivanyi and colleagues demonstrated that IgE blocks beta-2 receptors.[27] Since overproduction of IgE is central to all atopic diseases, this was a watershed moment in the world of allergy.[28]

The Beta-Adrenergic Theory has been cited in the scholarship of such noted investigators as Richard F. Lockey (former President of the American Academy of Allergy, Asthma, and Immunology),[29] Charles Reed (Chief of Allergy at Mayo Medical School),[30] and Craig Venter (Human Genome Project).[31]

John P. McGovern, President of the American Association of Allergy nominated Szentivanyi for The 1968 Nobel Prize in Medicine in recognition of The Beta Adrenergic Theory.

Asthma and sleep apnea

It is recognized with increasing frequency, that patients who have both obstructive sleep apnea (OSA) and bronchial asthma, often improve tremendously when the sleep apnea is diagnosed and treated.[32] CPAP is not effective in patients with nocturnal asthma only.[33]

Asthma and gastro-esophageal reflux disease

If gastro-esophageal reflux disease (GERD) is present, the patient may have repetitive episodes of acid aspiration. GERD may be common in difficult-to-control asthma, but according to one study, treating it does not seem to affect the asthma.[34]

Diagnosis

File:137 situation web 293x216.jpg
Spirometry test

Asthma is defined simply as reversible airway obstruction. Reversibility occurs either spontaneously or with treatment. The basic measurement is peak flow rates and the following diagnostic criteria are used by the British Thoracic Society:[35]

  • ≥20% difference on at least three days in a week for at least two weeks;
  • ≥20% improvement of peak flow following treatment, for example:
  • ≥20% decrease in peak flow following exposure to a trigger (e.g., exercise).

In many cases, a physician can diagnose asthma on the basis of typical findings in a patient's clinical history and examination. Asthma is strongly suspected if a patient suffers from eczema or other allergic conditions—suggesting a general atopic constitution—or has a family history of asthma. While measurement of airway function is possible for adults, most new cases are diagnosed in children who are unable to perform such tests. Diagnosis in children is based on a careful compilation and analysis of the patient's medical history and subsequent improvement with an inhaled bronchodilator medication. In adults, diagnosis can be made with a peak flow meter (which tests airway restriction), looking at both the diurnal variation and any reversibility following inhaled bronchodilator medication.

Testing peak flow at rest (or baseline) and after exercise can be helpful, especially in young asthmatics who may experience only exercise-induced asthma. If the diagnosis is in doubt, a more formal lung function test may be conducted. Once a diagnosis of asthma is made, a patient can use peak flow meter testing to monitor the severity of the disease.

Monitoring asthma with a peak flow meter on an ongoing basis assists with self monitoring of asthma. Peak flow readings can be charted on graph paper charts together with a record of symptoms or use peak flow charting software.[36] This allows patients to track their peak flow readings and pass information back to their doctor or nurse.[37]

In the Emergency Department doctors may use a capnography which measures the amount of exhaled carbon dioxide,[38] along with pulse oximetry which shows the amount of oxygen dissolved in the blood, to determine the severity of an asthma attack as well as the response to treatment.

More recently, exhaled nitric oxide has been studied as a breath test indicative of airway inflammation in asthma.

Differential diagnosis

Before diagnosing someone as asthmatic, alternative possibilities should be considered. A clinician taking a history should check whether the patient is using any known bronchoconstrictors (substances that cause narrowing of the airways, e.g., certain anti-inflammatory agents or beta-blockers).

Chronic obstructive pulmonary disease, which closely resembles asthma, is correlated with more exposure to cigarette smoke, an older patient, less symptom reversibility after bronchodilator administration (as measured by spirometry), and decreased likelihood of family history of atopy.

Pulmonary aspiration, whether direct due to dysphagia (swallowing disorder) or indirect (due to acid reflux), can show similar symptoms to asthma. However, with aspiration, fevers might also indicate aspiration pneumonia. Direct aspiration (dysphagia) can be diagnosed by performing a Modified Barium Swallow test and treated with feeding therapy by a qualified speech therapist. If the aspiration is indirect (from acid reflux) then treatment directed at this is indicated.

A majority of children who are asthma sufferers have an identifiable allergy trigger. Specifically, in a 2004 study, 71% had positive test results for more than 1 allergen, and 42% had positive test results for more than 3 allergens.[39]

The majority of these triggers can often be identified from the history; for instance, asthmatics with hay fever or pollen allergy will have seasonal symptoms, those with allergies to pets may experience an abatement of symptoms when away from home, and those with occupational asthma may improve during leave from work. Allergy tests can help identify avoidable symptom triggers.

After a pulmonary function test has been carried out, radiological tests, such as a chest X-ray or CT scan, may be required to exclude the possibility of other lung diseases. In some people, asthma may be triggered by gastroesophageal reflux disease, which can be treated with suitable antacids. Very occasionally, specialized tests after inhalation of methacholine — or, even less commonly, histamine — may be performed.

Asthma is categorized by the United States National Heart, Lung, and Blood Institute as falling into one of four categories: intermittent, mild persistent, moderate persistent and severe persistent. The diagnosis of "severe persistent asthma" occurs when symptoms are continual with frequent exacerbations and frequent night-time symptoms, result in limited physical activity and when lung function as measured by PEV or FEV1 tests is less than 60% predicted with PEF variability greater than 30%.

Prevention

Current treatment protocols recommend prevention medications such as an inhaled corticosteroid, which helps to suppress inflammation and reduces the swelling of the lining of the airways, in anyone who has frequent (greater than twice a week) need of relievers or who has severe symptoms. If symptoms persist, additional preventive drugs are added until the asthma is controlled. With the proper use of prevention drugs, asthmatics can avoid the complications that result from overuse of relief medications.

Asthmatics sometimes stop taking their preventive medication when they feel fine and have no problems breathing. This often results in further attacks, and no long-term improvement.

Preventive agents include the following.

  • Inhaled glucocorticoids are the most widely used prevention medications and normally come as inhaler devices (ciclesonide, beclomethasone, budesonide, flunisolide, fluticasone, mometasone, and triamcinolone).
    Long-term use of corticosteroids can have many side effects including a redistribution of fat, increased appetite, blood glucose problems and weight gain. In particular high doses of steroids may cause osteoporosis. For this reasons inhaled steroids are generally used for prevention, as their smaller doses are targeted to the lungs, unlike the higher doses of oral preparations. Nevertheless, patients on high doses of inhaled steroids may still require prophylactic treatment to prevent osteoporosis.
    Deposition of steroids in the mouth may cause a hoarse voice or oral thrush (due to decreased immunity). This may be minimised by rinsing the mouth with water after inhaler use, as well as by using a spacer which increases the amount of drug that reaches the lungs.
  • Leukotriene modifiers (montelukast, zafirlukast, pranlukast, and zileuton) provide anti-inflammatory effect similar to inhaled corticosteroids.
  • Mast cell stabilizers (cromoglicate (cromolyn), and nedocromil).
  • Antimuscarinics/anticholinergics (ipratropium, oxitropium, and tiotropium), which have a mixed reliever and preventer effect. These are often used to reduce bronchospasm when inhaled steroids do not produce sufficient relief.
  • Methylxanthines (theophylline and aminophylline), which are sometimes considered if sufficient control cannot be achieved with inhaled glucocorticoids (or leukotriene modifiers) and long-acting β-agonists alone.
  • Antihistamines, often used to treat allergic effects that may underlie the chronic inflammation.
  • Hyposensitization, (also known as immunodesensitisation therapy) may be recommended in some cases where allergy is the suspected cause or trigger of asthma. Depending on the allergen, it can be given orally or by injection.
  • Omalizumab, an IgE blocker; this can help patients with severe allergic asthma that does not respond to other drugs. However, it is expensive and must be injected.
  • Methotrexate is occasionally used in some difficult-to-treat patients.
  • If chronic acid indigestion (GERD) contributes to a patient's asthma, it should also be treated, because it may prolong the respiratory problem.

Trigger avoidance

As is common with respiratory disease, smoking is believed to adversely affect asthmatics in several ways, including an increased severity of symptoms, a more rapid decline of lung function, and decreased response to preventive medications.[40] Automobile emissions are considered an even more significant cause and aggravating factor.[41] Asthmatics who smoke or who live near traffic [1] typically require additional medications to help control their disease. Furthermore, exposure of both non-smokers and smokers to wood smoke, gas stove fumes and second-hand smoke is detrimental, resulting in more severe asthma, more emergency room visits, and more asthma-related hospital admissions.[42] Smoking cessation and avoidance of second-hand smoke is strongly encouraged in asthmatics.[43]

For those in whom exercise can trigger an asthma attack (exercise-induced asthma), higher levels of ventilation and cold, dry air tend to exacerbate attacks. For this reason, activities in which a patient breathes large amounts of cold air, such as skiing and running, tend to be worse for asthmatics, whereas swimming in an indoor, heated pool, with warm, humid air, or a shower is less likely to provoke a response.[4]

Air Filters

If an asthmatic lives with a smoker, use of an air filter or room air cleaner is likely to be helpful. However, room air cleaners do not remove small allergen particles that are caused by local disturbances, such as the microscopic house dust mite feces on and around pillows, rugs, furniture, etc.[44]

Treatment

The most effective treatment for asthma is identifying triggers, such as pets or aspirin, and limiting or eliminating exposure to them. If trigger avoidance is insufficient, medical treatment is available. Desensitization is currently the only known "cure" to the disease.[45] Other forms of treatment include relief medication, prevention medication, long-acting β2-agonists, and emergency treatment.

Medical

The specific medical treatment recommended to patients with asthma depends on the severity of their illness and the frequency of their symptoms. Specific treatments for asthma are broadly classified as relievers, preventers and emergency treatment. The Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (EPR-2)[43] of the U.S. National Asthma Education and Prevention Program, and the British Guideline on the Management of Asthma[46] are broadly used and supported by many doctors. On August 29, 2007 the final Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma was officially released. Bronchodilators are recommended for short-term relief in all patients. For those who experience occasional attacks, no other medication is needed. For those with mild persistent disease (more than two attacks a week), low-dose inhaled glucocorticoids or alternatively, an oral leukotriene modifier, a mast-cell stabilizer, or theophylline may be administered. For those who suffer daily attacks, a higher dose of glucocorticoid in conjunction with a long-acting inhaled β-2 agonist may be prescribed; alternatively, a leukotriene modifier or theophylline may substitute for the β-2 agonist. In severe asthmatics, oral glucocorticoids may be added to these treatments during severe attacks.

Pharmaceutical

Symptomatic control of episodes of wheezing and shortness of breath is generally achieved with fast-acting bronchodilators. These are typically provided in pocket-sized, metered-dose inhalers (MDIs). In young sufferers, who may have difficulty with the coordination necessary to use inhalers, or those with a poor ability to hold their breath for 10 seconds after inhaler use (generally the elderly), an asthma spacer (see top image) is used. The spacer is a plastic cylinder that mixes the medication with air in a simple tube, making it easier for patients to receive a full dose of the drug and allows for the active agent to be dispersed into smaller, more fully inhaled bits.

A nebulizer which provides a larger, continuous dose can also be used. Nebulizers work by vaporizing a dose of medication in a saline solution into a steady stream of foggy vapour, which the patient inhales continuously until the full dosage is administered. There is no clear evidence, however, that they are more effective than inhalers used with a spacer. Nebulizers may be helpful to some patients experiencing a severe attack. Such patients may not be able to inhale deeply, so regular inhalers may not deliver medication deeply into the lungs, even on repeated attempts. Since a nebulizer delivers the medication continuously, it is thought that the first few inhalations may relax the airways enough to allow the following inhalations to draw in more medication.

Relievers include:

  • Short-acting, selective beta2-adrenoceptor agonists, such as salbutamol (albuterol USAN), levalbuterol, terbutaline and bitolterol.
    Tremors, the major side effect, have been greatly reduced by inhaled delivery, which allows the drug to target the lungs specifically; oral and injected medications are delivered throughout the body. There may also be cardiac side effects at higher doses (due to Beta-1 agonist activity), such as elevated heart rate or blood pressure. Patients must be cautioned against using these medicines too frequently, as with such use their efficacy may decline, producing desensitization resulting in an exacerbation of symptoms which may lead to refractory asthma and death.
  • Older, less selective adrenergic agonists, such as inhaled epinephrine and ephedrine tablets, have also been used. Cardiac side effects occur with these agents at either similar or lesser rates to albuterol.[47] [48] When used solely as a relief medication, inhaled epinephrine has been shown to be an effective agent to terminate an acute asthmatic exacerbation.[47] In emergencies, these drugs were sometimes administered by injection. Their use via injection has declined due to related adverse effects.
  • Anticholinergic medications, such as ipratropium bromide may be used instead. They have no cardiac side effects and thus can be used in patients with heart disease; however, they take up to an hour to achieve their full effect and are not as powerful as the β2-adrenoreceptor agonists.
  • Inhaled glucocorticoids are usually considered preventive medications while oral glucocorticoids are often used to supplement treatment of a severe attack. They should be used twice daily in children with mild to moderate persistent asthma.[49] A randomized controlled trial has demonstrated the benefit of 250 microg beclomethasone when taken as an as-needed combination inhaler with 100 microg of albuterol.[50]

Long-acting β2-agonists

A typical inhaler, of Serevent (salmeterol), a long-acting bronchodilator.

Long-acting bronchodilators (LABD) are similar in structure to short-acting selective beta2-adrenoceptor agonists, but have much longer side chains resulting in a 12-hour effect, and are used to give a smoothed symptomatic relief (used morning and night). While patients report improved symptom control, these drugs do not replace the need for routine preventers, and their slow onset means the short-acting dilators may still be required. In November 2005, the American FDA released a health advisory alerting the public to findings that show the use of long-acting β2-agonists could lead to a worsening of symptoms, and in some cases death.[51] In December 2008, members of the FDA's drug-safety office recommended withdrawing approval for these medications in children. Discussion is ongoing about their use in adults.[52]

Currently available long-acting beta2-adrenoceptor agonists include salmeterol, formoterol, bambuterol, and sustained-release oral albuterol. Combinations of inhaled steroids and long-acting bronchodilators are becoming more widespread; the most common combination currently in use is fluticasone/salmeterol (Advair in the United States, and Seretide in the United Kingdom). Another combination is budesonide/formoterol which is commercially known as Symbicort.

A recent meta-analysis of the roles of long-acting beta-agonists may indicate a danger to asthma patients. The study, published in the Annals of Internal Medicine in 2006, found that long-acting beta-agonists increased the risk for asthma hospitalizations and asthma deaths 2- to 4-fold, compared with placebo.[53] "These agents can improve symptoms through bronchodilation at the same time as increasing underlying inflammation and bronchial hyper-responsiveness, thus worsening asthma control without any warning of increased symptoms," said Shelley Salpeter in a press release after the publication of the study. The release goes on to say that "Three common asthma inhalers containing the drugs salmeterol or formoterol may be causing four out of five US asthma-related deaths per year and should be taken off the market".[54] This assertion is viewed by many asthma specialists as being inaccurate. Dr. Hal Nelson, in a recent letter to the Annals of Internal Medicine, points out the following:

"Salpeter and colleagues also assert that salmeterol may be responsible for 4000 of the 5000 asthma-related deaths that occur in the United States annually. However, when salmeterol was introduced in 1994, more than 5000 asthma-related deaths occurred per year. Since the peak of asthma deaths in 1996, salmeterol sales have increased about 5-fold, while overall asthma mortality rates have decreased by about 25%, despite a continued increase in asthma diagnoses. In fact, according to the most recent data from the National Center for Health Statistics, U.S. asthma mortality rates peaked in 1996 (with 5667 deaths) and have decreased steadily since. The last available data, from 2004, indicate that 3780 deaths occurred. Thus, the suggestion that a vast majority of asthma deaths could be attributable to LABA use is inconsistent with the facts."

Dr. Shelley Salpeter, in a letter to the Annals of Internal Medicine, responds to the comments of Dr. Nelson, as follows:

"It is true that the asthma death rate increased after salmeterol was introduced, then peaked and is now starting to decline despite continued use of the long-acting beta-agonists. This trend in death rates can best be explained by examining the ratio of beta-agonist use to inhaled corticosteroids... In the recent past, inhaled corticosteroid use has increased steadily while long-acting beta-agonist use has begun to stabilize and short-acting beta-agonist use has declined... Using this estimate, we can imagine that if long-acting beta-agonists were withdrawn from the market while maintaining high inhaled corticosteroid use, the death rate in the United States could be reduced significantly..."

Emergency

When an asthma attack is unresponsive to a patient's usual medication, other treatments are available to the physician or hospital:[55]

Non-medical treatments

Many asthmatics, like those who suffer from other chronic disorders, use alternative treatments; surveys show that roughly 50% of asthma patients use some form of unconventional therapy.[57][58] There is little data to support the effectiveness of most of these therapies. The Buteyko method of controlling hyperventilation hypocapnia has shown in five randomized controlled trials to result in a significant reduction in need for medications without an effect on bronchial hyperreactivity or lung function.[59][60][61][62][63] In May 2008 the updated British Guidelines for the Management of Asthma endorsed Buteyko Technique.[64] A Cochrane systematic review of acupuncture for asthma found no evidence of efficacy.[65] A similar review of air ionisers found no evidence that they improve asthma symptoms or benefit lung function; this applied equally to positive and negative ion generators.[66] Another systematic study reviewed a range of dust mite control measures, including air filtration, chemicals to kill mites, vacuuming, mattress covers and others. Overall these methods had no effect on asthma symptoms .[67] A study of "manual therapies" for asthma, including osteopathic, chiropractic, physiotherapeutic and respiratory therapeutic manoeuvres, found there is insufficient evidence to support or refute their use in treating asthma;[68] these manoeuvers include various osteopathic and chiropractic techniques to "increase movement in the rib cage and the spine to try and improve the working of the lungs and circulation"; chest tapping, shaking, vibration, and the use of "postures to help shift and cough up phlegm." One meta-analysis finds that homeopathy may have a potentially mild benefit in reducing the intensity of symptoms.[69] However, the number of patients involved in the analysis was small, and subsequent studies have not supported this finding.[70] Several small trials have suggested some benefit from various yoga practices, ranging from integrated yoga programs,[71] yogasanas, Pranayama, meditation, and kriyas, to sahaja yoga,[72] a form of 'new religious' meditation.

Treatment controversies

In November 2007 The New York Times reported a review of more than 500 studies finding that independently backed studies on inhaled corticosteroids are up to four times more likely to find adverse effects than studies paid for by drug companies.[73][74]

Prognosis

The prognosis for asthmatics is good; especially for children with mild disease. For asthmatics diagnosed during childhood, 54% will no longer carry the diagnosis after a decade. The extent of permanent lung damage in asthmatics is unclear. Airway remodelling is observed, but it is unknown whether these represent harmful or beneficial changes.[18] Although conclusions from studies are mixed, most studies show that early treatment with glucocorticoids prevents or ameliorates decline in lung function as measured by several parameters.[75] For those who continue to suffer from mild symptoms, corticosteroids can help most to live their lives with few disabilities. The mortality rate for asthma is low, with around 6000 deaths per year in a population of some 10 million patients in the United States.[4] Better control of the condition may help prevent some of these deaths.

Epidemiology

The prevalence of childhood asthma has increased since 1980, especially in younger children.

The highest levels of asthma in the world according to the Global INitiative for Asthma (GINA) report of February 2004[76] occurred for about 30% of children in the United Kingdom, New Zealand and Australia, or 20% of children in Peru, New Zealand and Australia according to the method of interview, and for about 25% of adults in Great Britain, Australia and Canada. The United States also ranks highly. More than 6% of children in the United States have been diagnosed with asthma, a 75% increase in recent decades. The rate soars to 40% among some populations of urban children.[citation needed]

Current research suggests that the prevalence of childhood asthma has been increasing. According to the Centers for Disease Control and Prevention's National Health Interview Surveys, some 9% of US children below 18 years of age had asthma in 2001, compared with just 3.6% in 1980 (see figure). The World Health Organization (WHO) reports that some 8% of the Swiss population suffers from asthma today, compared with just 2% some 25–30 years ago.[77] Although asthma is more common in affluent countries, it is by no means a problem restricted to the affluent; the WHO estimate that there are between 15 and 20 million asthmatics in India. In the U.S., urban residents, Hispanics, and African Americans are affected more than the population as a whole. Globally, asthma is responsible for around 180,000 deaths annually.[77]

Population disparities

Asthma prevalence, morbidity, mortality, and drug response vary greatly across populations. There is an almost 30-fold difference in asthma prevalence between some of the countries included in the International Study of Asthma and Allergy in Childhood [2], with a trend toward more developed and westernized countries having higher asthma prevalence. Westernization can’t explain the entire difference in asthma prevalence between countries, however, and the disparities may also be affected by differences in genetic, social and environmental risk factors.[8] There are also worldwide disparities in asthma mortality, which is most common in low to middle income countries.[78]

Asthma prevalence in the US is higher than in most other countries in the world, but varies drastically between diverse US populations.[8] In the US, asthma prevalence is highest in Puerto Ricans, African Americans, Filipinos and Native Hawaiians, and lowest in Mexicans and Koreans.[79][80][81] Mortality rates follow similar trends, and response to albuterol is lower in Puerto Ricans than in African Americans or Mexicans.[82][83] As with worldwide asthma disparities, differences in asthma prevalence, mortality, and drug response in the US may be explained by differences in genetic, social and environmental risk factors.

Asthma prevalence also differs between populations of the same ethnicity who are born and live in different places.[84] US-born Mexican populations, for example, have higher asthma rates than non-US born Mexican populations that are living in the US.[85] This probably reflects differences in social and environmental risk factors associated with acculturation to the US.[citation needed]

Asthma prevalence and asthma deaths also differ by gender. Males are more likely to be diagnosed with asthma as children, but asthma is more likely to persist into adulthood in females. Sixty five percent more adult women than men will die from asthma. This difference may be attributable to hormonal differences, among other things. In support of this, girls who reach puberty before age 12 were found to have a later diagnosis of asthma more than twice as much as girls who reach puberty after age 12. Asthma is also the number one cause of missed days from school.

Socioeconomic factors

The incidence of asthma is highest among low-income populations (asthma deaths are most common in low to middle income countries [3]), which in the western world are disproportionately ethnic minorities[86] and are more likely to live near industrial areas. Additionally, asthma has been strongly associated with the presence of cockroaches in living quarters, which is more likely in such neighborhoods.

Asthma incidence and quality of treatment varies among different racial groups, though this may be due to correlations with income (and thus affordability of health care) and geography. For example, Black Americans are less likely to receive outpatient treatment for asthma despite having a higher prevalence of the disease. They are much more likely to have emergency room visits or hospitalization for asthma, and are three times as likely to die from an asthma attack compared to whites. The prevalence of "severe persistent" asthma is also greater in low-income communities compared with communities with better access to treatment.[87][88]

Asthma and athletics

Asthma appears to be more prevalent in athletes than in the general population. One survey of participants in the 1996 Summer Olympic Games, in Atlanta, Georgia, U.S., showed that 15% had been diagnosed with asthma, and that 10% were on asthma medication.[89] These statistics have been questioned on at least two bases. Athletes with mild asthma may be more likely to be diagnosed with the condition than non-athletes, because even subtle symptoms may interfere with their performance and lead to pursuit of a diagnosis. It has also been suggested that some professional athletes who do not suffer from asthma claim to do so in order to obtain special permits to use certain performance-enhancing drugs.[citation needed]

There appears to be a relatively high incidence of asthma in sports such as cycling, mountain biking, and long-distance running, and a relatively lower incidence in weightlifting and diving. It is unclear how much of these disparities are from the effects of training in the sport, and from self-selection of sports that may appear to minimize the triggering of asthma.[89][90]

In addition, there exists a variant of asthma called exercise-induced asthma that shares many features with allergic asthma. It may occur either independently, or concurrent with the latter. Exercise studies may be helpful in diagnosing and assessing this condition.

History

Asthma was long considered a psychosomatic disease, and

... during the 1930s–50s, was even known as one of the 'holy seven' psychosomatic illnesses. At that time, psychoanalytic theories described the aetiology of asthma as psychological, with treatment often primarily involving psychoanalysis and other 'talking cures'. As the asthmatic wheeze was interpreted as the child's suppressed cry for his or her mother, psychoanalysts viewed the treatment of depression as especially important for individuals with asthma.[91]

See also

Wikimedia Commons has media related to Asthma.

References

  1. ^ "Asthma: What Causes Asthma". Asthma and Allergy Foundation of America. Retrieved 2008-01-03.
  2. ^ Zhao J, Takamura M, Yamaoka A, Odajima Y, Iikura Y (2002). "Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood". Pediatr Allergy Immunol. 13 (1): 47–50. doi:10.1034/j.1399-3038.2002.00051.x. PMID 12000498. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Lilly CM (2005). "Diversity of asthma: evolving concepts of pathophysiology and lessons from genetics". J. Allergy Clin. Immunol. 115 (4 Suppl): S526–31. doi:10.1016/j.jaci.2005.01.028. PMID 15806035.
  4. ^ a b c d McFadden ER, Jr (2004). "Asthma". Harrison's Principles of Internal Medicine (Kasper DL, Fauci AS, Longo DL, et al (eds)) (16th ed. ed.). New York: McGraw-Hill. pp. 1508–16. {{cite book}}: |edition= has extra text (help)
  5. ^ Longmore, Murray; et al. (2007). Oxford Handbook of Clinical Medicine (7th ed. ed.). Oxford University Press. ISBN 978-0198568377. {{cite book}}: |edition= has extra text (help); Explicit use of et al. in: |first= (help)
  6. ^ a b Martinez FD (2007). "Genes, environments, development and asthma: a reappraisal". Eur Respir J. 29 (1): 179–84. doi:10.1183/09031936.00087906. PMID 17197483.
  7. ^ Choudhry S, Seibold MA, Borrell LN; et al. (2007). "Dissecting complex diseases in complex populations: asthma in latino americans". Proc Am Thorac Soc. 4 (3): 226–33. doi:10.1513/pats.200701-029AW. PMID 17607004. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  8. ^ a b c d e f Gold DR,Wright R (2005). "Population disparities in asthma". Annu Rev Public Health. 26: 89–113. doi:10.1146/annurev.publhealth.26.021304.144528. PMID 15760282.
  9. ^ "California Children's Health Study".
  10. ^ a b Thavagnanam S, Fleming J, Bromley A, Shields MD, Cardwell, CR (2007). "A meta-analysis of the association between Caesarean section and childhood asthma". Clin. And Exper. Allergy. online ahead of print: 629. doi:10.1111/j.1365-2222.2007.02780.x.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Harju TH, Leinonen M, Nokso-Koivisto J; et al. (2006). "Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma". Thorax. 61 (7): 579–84. doi:10.1136/thx.2005.056291. PMID 16517571. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  12. ^ Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG (2005). "Macrolides for chronic asthma". Cochrane Database Syst Rev (4): CD002997. doi:10.1002/14651858.CD002997.pub3. PMID 16235309.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ a b Marra F, Lynd L, Coombes M; et al. (2006). "Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis". Chest. 129 (3): 610–8. doi:10.1378/chest.129.3.610. PMID 16537858. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  14. ^ Jeremy Laurance. "Asthma blamed on cleaning sprays and air fresheners".
  15. ^ a b c Ober C,Hoffjan S (2006). "Asthma genetics 2006: the long and winding road to gene discovery". Genes Immun. 7 (2): 95–100. doi:10.1038/sj.gene.6364284. PMID 16395390.
  16. ^ Bouzigon E, Corda E, Aschard H; et al. (2008). "Effect of 17q21 Variants and Smoking Exposure in Early-Onset Asthma". The New England journal of medicine. doi:10.1056/NEJMoa0806604. PMID 18923164. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  17. ^ a b Martinez FD (2007). "CD14, endotoxin, and asthma risk: actions and interactions". Proc Am Thorac Soc. 4 (3): 221–5. doi:10.1513/pats.200702-035AW. PMID 17607003.
  18. ^ a b Maddox L, Schwartz DA (2002). "The pathophysiology of asthma". Annu. Rev. Med. 53: 477–98. doi:10.1146/annurev.med.53.082901.103921. PMID 11818486.
  19. ^ "Lecture 14: Hypersensitivity". Retrieved 2008-09-18.
  20. ^ "Allergy & Asthma Disease Management Center: Ask the Expert". Retrieved 2008-09-18.
  21. ^ Jenkins C, Costello J, Hodge L (2004). "Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice". BMJ. 328 (7437): 434. doi:10.1136/bmj.328.7437.434. PMID 14976098.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Nemery B, Hoet PH, Nowak D (2002). "Indoor swimming pools, water chlorination and respiratory health". Eur. Respir. J. 19 (5): 790–3. doi:10.1183/09031936.02.00308602. PMID 12030714.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. ^ about.com article
  24. ^ Asthma and Altitude
  25. ^ Szentivanyi, Andor (1968). "The Beta Adrenergic Theory of the Atopic Abnormality in Asthma". {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |jounal= ignored (help)
  26. ^ Lockey, Richard, In lasting tribute: Andor Szentivanyi, MD. J. Allergy and Clinical Immunology, January, 2006
  27. ^ Szentivanyi A., Ali K., Calderon EG., Brooks SM., Coffey RG., Lockey RF. (1993). "The in vitro effect of Imunnoglobulin E {IgE} on cyclic AMP concentrations in A549 human pulmonary epithelial cells with or without beta adrenergic stimulation". J. Allergy Clin Immunol. 91: 379.{{cite journal}}: CS1 maint: multiple names: authors list (link) - Part of Abstracts from:
    "50th Anniversary of the American Academy of Allergy and Immunology. 49th Annual Meeting. Chicago, Illinois, March 12-17, 1993. Abstracts". J. Allergy Clin. Immunol. 91 (1 Pt 2): 141–379. 1993. PMID 8421135.
  28. ^ Kowalak JP, Hughes AS et al (eds), ed. (2001). Professional Guide To Diseases (7th ed. ed.). Springhouse. {{cite book}}: |edition= has extra text (help); |editor= has generic name (help)
  29. ^ Lockey, Richard F. (2006-04-28). "Anaphylaxis: Synopsis". Allergic Diseases Resource Center. World Allergy Organization. {{cite web}}: Unknown parameter |accessmonthday= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)[dead link]
  30. ^ Ouellette JJ, Reed CE (1967). "The effect of partial beta adrenergic blockade on the bronchial response of hay fever subjects to ragweed aerosol". J Allergy. 39 (3): 160–6. doi:10.1016/0021-8707(67)90033-0. PMID 5227155.
  31. ^ Fraser CM, Venter JC (1980). "The synthesis of beta-adrenergic receptors in cultured human lung cells: induction by glucocorticoids". Biochem. Biophys. Res. Commun. 94 (1): 390–7. doi:10.1016/S0006-291X(80)80233-6. PMID 6248064.
  32. ^ "Breathing disorders during sleep are common among asthmatics, may help predict severe asthma" (Press release). University of Michigan Health System. May 25, 2005. Retrieved 2006-09-23.
  33. ^ Basner, Robert C. (2006-07-25). "Asthma and OSA". ASAA Resources > Publications. American Sleep Apnea Association. {{cite web}}: Unknown parameter |accessmonthday= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  34. ^ Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG (2005). "Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome". Chest. 127 (4): 1227–31. doi:10.1378/chest.127.4.1227. PMID 15821199.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  35. ^ Pinnock H, Shah R (2007). "Asthma". BMJ. 334 (7598): 847–50. doi:10.1136/bmj.39140.634896.BE. PMID 17446617.
  36. ^ "Peak flow charting software".
  37. ^ "'Be in control' pack" (PDF). Asthma UK. Retrieved 2007-11-19.
  38. ^ Corbo J, Bijur P, Lahn M, Gallagher EJ (2005). "Concordance between capnography and arterial blood gas measurements of carbon dioxide in acute asthma". Annals of emergency medicine. 46 (4): 323–7. doi:10.1016/j.annemergmed.2004.12.005. PMID 16187465.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  39. ^ Vargas PA, Simpson PM, Gary Wheeler J; et al. (2004). "Characteristics of children with asthma who are enrolled in a Head Start program". J. Allergy Clin. Immunol. 114 (3): 499–504. doi:10.1016/j.jaci.2004.05.025. PMID 15356547. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  40. ^ Thomson NC, Spears M (2005). "The influence of smoking on the treatment response in patients with asthma". Curr Opin Allergy Clin Immunol. 5 (1): 57–63. PMID 15643345.
  41. ^ EWG || Auto Asthma Index
  42. ^ Eisner MD, Yelin EH, Katz PP, Earnest G, Blanc PD (2002). "Exposure to indoor combustion and adult asthma outcomes: environmental tobacco smoke, gas stoves, and woodsmoke". Thorax. 57 (11): 973–8. doi:10.1136/thorax.57.11.973. PMID 12403881.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  43. ^ a b National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health pub no 97–4051. Bethesda, MD, 1997. (PDF)
  44. ^ Asthma and Air Filters Asthma and Air Filters[dead link]
  45. ^ Abramson MJ, Puy RM, Weiner JM (1995). "Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials". Am. J. Respir. Crit. Care Med. 151 (4): 969–74. PMID 7697274.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  46. ^ "British Guideline on the Management of Asthma" (PDF). Scottish Intercollegiate Guidelines Network. 2008. Retrieved 2008-08-04.
  47. ^ a b Hendeles L, Marshik PL, Ahrens R, Kifle Y, Shuster J (2005). "Response to nonprescription epinephrine inhaler during nocturnal asthma". Ann. Allergy Asthma Immunol. 95 (6): 530–4. PMID 16400891.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  48. ^ Rodrigo GJ, Nannini LJ (2006). "Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials". Am J Emerg Med. 24 (2): 217–22. doi:10.1016/j.ajem.2005.10.008. PMID 16490653.
  49. ^ "BestBets: Inhaled steroids in the treatment of mild to moderate persistent asthma in children: once or twice daily administration?". Retrieved December 16, 2008.
  50. ^ Papi A, Canonica GW, Maestrelli P; et al. (2007). "Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma". N. Engl. J. Med. 356 (20): 2040–52. doi:10.1056/NEJMoa063861. PMID 17507703. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  51. ^ "Serevent Diskus, Advair Diskus, and Foradil Information (Long Acting Beta Agonists) - Drug information". FDA. 2006-03-03. {{cite web}}: Check date values in: |year= (help)
  52. ^ "FDA sees asthma drug risks - Yahoo! News". Retrieved December 5, 2008.
  53. ^ Salpeter S, Buckley N, Ormiston T, Salpeter E (2006). "Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths". Ann Intern Med. 144 (12): 904–12. PMID 16754916.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  54. ^ Ramanujan, Krishna (2006-06-09). "Common asthma inhalers cause up to 80 percent of asthma-related deaths, Cornell and Stanford researchers assert". Cornell Chronicle Online. Cornell News Service. Retrieved 2006-09-23.
  55. ^ Rodrigo GJ, Rodrigo C, Hall JB (2004). "Acute asthma in adults: a review". Chest. 125 (3): 1081–102. doi:10.1378/chest.125.3.1081. PMID 15006973.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  56. ^ Rodrigo G (2005). "Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma". Am J Respir Crit Care Med. 171 (11): 1231–6. doi:10.1164/rccm.200410-1415OC. PMID 15764724.
  57. ^ Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD (2001). "Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis : data from a population-based survey". Chest. 120 (5): 1461–7. doi:10.1378/chest.120.5.1461. PMID 11713120.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  58. ^ Shenfield G, Lim E, Allen H (2002). "Survey of the use of complementary medicines and therapies in children with asthma". J Paediatr Child Health. 38 (3): 252–7. doi:10.1046/j.1440-1754.2002.00770.x. PMID 12047692.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  59. ^ Cowie RL, Conley DP, Underwood MF, Reader PG (2008). "A randomised controlled trial of the Buteyko technique as an adjunct to conventional management of asthma". Respir Med. 102 (5): 726–32. doi:10.1016/j.rmed.2007.12.012. PMID 18249107. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  60. ^ Cooper S, Oborne J, Newton S; et al. (2003). "Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial". Thorax. 58 (8): 674–9. PMC 1746772. PMID 12885982. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  61. ^ Bowler SD, Green A, Mitchell CA (1998). "Buteyko breathing techniques in asthma: a blinded randomised controlled trial". Med. J. Aust. 169 (11–12): 575–8. PMID 9887897.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  62. ^ McHugh P, Aitcheson F, Duncan B, Houghton F (2003). "Buteyko Breathing Technique for asthma: an effective intervention". N. Z. Med. J. 116 (1187): U710. PMID 14752538. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  63. ^ Opat AJ, Cohen MM, Bailey MJ, Abramson MJ (2000). "A clinical trial of the Buteyko Breathing Technique in asthma as taught by a video". J Asthma. 37 (7): 557–64. PMID 11059522.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  64. ^ BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA. May 2008.
  65. ^ McCarney RW, Brinkhaus B, Lasserson TJ, Linde K (2004). "Acupuncture for chronic asthma". Cochrane Database Syst Rev (1): CD000008. doi:10.1002/14651858.CD000008.pub2. PMID 14973944.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  66. ^ Blackhall K, Appleton S, Cates CJ (2003). "Ionisers for chronic asthma". Cochrane Database Syst Rev (3): CD002986. doi:10.1002/14651858.CD002986. PMID 12917939.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  67. ^ PC Gøtzsche, HK Johansen (2008). "House dust mite control measures for asthma". Cochrane Database Syst Rev (2): CD001187. doi:10.1002/14651858.CD001187.pub3.
  68. ^ Hondras MA, Linde K, Jones AP (2005). "Manual therapy for asthma". Cochrane Database Syst Rev (2): CD001002. doi:10.1002/14651858.CD001002.pub2. PMID 15846609.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  69. ^ Reilly D, Taylor MA, Beattie NG; et al. (1994). "Is evidence for homoeopathy reproducible?". Lancet. 344 (8937): 1601–6. doi:10.1016/S0140-6736(94)90407-3. PMID 7983994. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  70. ^ White A, Slade P, Hunt C, Hart A, Ernst E (2003). "Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial". Thorax. 58 (4): 317–21. doi:10.1136/thorax.58.4.317. PMID 12668794.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  71. ^ Nagendra HR, Nagarathna R (1986). "An integrated approach of yoga therapy for bronchial asthma: a 3-54-month prospective study". J Asthma. 23 (3): 123–37. doi:10.3109/02770908609077486. PMID 3745111.
  72. ^ Manocha R, Marks GB, Kenchington P, Peters D, Salome CM (2002). "Sahaja yoga in the management of moderate to severe asthma: a randomised controlled trial". Thorax. 57 (2): 110–5. doi:10.1136/thorax.57.2.110. PMID 11828038.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  73. ^ Nagourney E (2007-11-13). "For the Record: In Tests of Inhalers, Results May Depend on Who Pays". The New York Times. Retrieved 2007-12-02. {{cite news}}: Italic or bold markup not allowed in: |publisher= (help)
  74. ^ Nieto A, Mazon A, Pamies R; et al. (2007). "Adverse effects of inhaled corticosteroids in funded and nonfunded studies". Arch. Intern. Med. 167 (19): 2047–53. doi:10.1001/archinte.167.19.2047. PMID 17954797. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  75. ^ Beckett PA, Howarth PH (2003). "Pharmacotherapy and airway remodelling in asthma?". Thorax. 58 (2): 163–74. doi:10.1136/thorax.58.2.163. PMID 12554904.
  76. ^ Masoli, Matthew (2004). "Global Burden of Asthma(TM)" (PDF). Retrieved 2008-08-08. {{cite web}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  77. ^ a b World Health Organization. "Bronchial asthma: scope of the problem". Retrieved 2005-08-23.
  78. ^ World Health Organization. "WHO: Asthma". Retrieved 2007-12-29.
  79. ^ Lara M, Akinbami L, Flores G,Morgenstern H (2006). "Heterogeneity of childhood asthma among Hispanic children: Puerto Rican children bear a disproportionate burden". Pediatrics. 117 (1): 43–53. doi:10.1542/peds.2004-1714. PMID 16396859.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  80. ^ Davis AM, Kreutzer R, Lipsett M, King G,Shaikh N (2006). "Asthma prevalence in Hispanic and Asian American ethnic subgroups: results from the California Healthy Kids Survey". Pediatrics. 118 (2): e363–70. doi:10.1542/peds.2005-2687. PMID 16882779.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  81. ^ Johnson DB, Oyama N, LeMarchand L,Wilkens L (2004). "Native Hawaiians mortality, morbidity, and lifestyle: comparing data from 1982, 1990, and 2000". Pac Health Dialog. 11 (2): 120–30. PMID 16281689.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  82. ^ Naqvi M, Thyne S, Choudhry S; et al. (2007). "Ethnic-specific differences in bronchodilator responsiveness among african americans, puerto ricans, and mexicans with asthma". J Asthma. 44 (8): 639–48. doi:10.1080/02770900701554441. PMID 17943575. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  83. ^ Burchard EG, Avila PC, Nazario S; et al. (2004). "Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma". Am J Respir Crit Care Med. 169 (3): 386–92. doi:10.1164/rccm.200309-1293OC. PMID 14617512. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  84. ^ Gold DR,Acevedo-Garcia D (2005). "Immigration to the United States and acculturation as risk factors for asthma and allergy". J Allergy Clin Immunol. 116 (1): 38–41. doi:10.1016/j.jaci.2005.04.033. PMID 15990770.
  85. ^ Eldeirawi KM,Persky VW (2006). "Associations of acculturation and country of birth with asthma and wheezing in Mexican American youths". J Asthma. 43 (4): 279–86. doi:10.1080/0277090060022869. PMID 16809241.
  86. ^ "Patient/Public Education: Fast Facts - Asthma Demographics/Statistics". American Academy of Allergy Asthma & Immunology. Retrieved 2006-05-02.
  87. ^ National Heart, Lung, and Blood Institute (2004). "Morbidity & Mortality: 2004 Chart Book On Cardiovascular, Lung, and Blood Diseases". National Institutes of Health. {{cite journal}}: Cite journal requires |journal= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  88. ^ National Center for Health Statistics (7 April 2006). "Asthma Prevalence, Health Care Use and Mortality, 2002". Centers for Disease Control and Prevention.
  89. ^ a b Weiler JM, Layton T, Hunt M (1998). "Asthma in United States Olympic athletes who participated in the 1996 Summer Games". J. Allergy Clin. Immunol. 102 (5): 722–6. doi:10.1016/S0091-6749(98)70010-7. PMID 9819287.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  90. ^ Helenius I, Haahtela T (2000). "Allergy and asthma in elite summer sport athletes". J. Allergy Clin. Immunol. 106 (3): 444–52. doi:10.1067/mai.2000.107749. PMID 10984362.
  91. ^ Opolski M, Wilson I (2005). "Asthma and depression: a pragmatic review of the literature and recommendations for future research". Clin Pract Epidemol Ment Health. 1: 18. doi:10.1186/1745-0179-1-18. PMC 1253523. PMID 16185365. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: unflagged free DOI (link)

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Asthma&oldid=257752442"